Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010
A 31-Year-Old Woman with a Transformed Low-Grade Glioma
JAMA 303:967-976, Warnke,P.C., 2010
Drip, Ship, and Retrieve: Cooperative Recanalization Therapy in Acute Basilar Artery Occlusion
Stroke 41:722-726, Pfefferkorn,T., et al, 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Safety of tPA in Stroke Mimics and Neuroimaging-Negative Cerebral Ischemia
Neurol 74:1340-1345, 1336, Chernyshev,O.Y., et al, 2010
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
Arch Neurol 67:559-563, Prabhakaran,S., et al, 2010
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
Progressive Multifocal Leukoencephalopathy in Individuals with Minimal or Occult Immunosuppression
JNNP 81:247-254, Gheuens,S., et al, 2010
The "Golden Hour" and Acute brain Ischemia: Presenting Features and Lytic Therapy in >30000 Patients Arriving Within 60 Minutes of Stroke Onset
Stroke 41:1431-1439, Saver,J.L., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Safety of Performing CT Angiography in Stroke Patients Treated With Intravenous Thrombolysis
JNNP 81:783-787, Aulick�,P., et al, 2010
Is Thrombolysis Safe in the Elderly? Analysis of a National Database
Stroke 41:2259-2264, Alshekhlee,A.,et al, 2010
Intravenous Thrombolysis in a Patient with Known Cavernous Malformation: A First Case Report
Am J Emerg Med 28:117.e1-117.e3, Henninger, N.,et al, 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Reversible Extralimbic Paraneoplastic Encephalopathies with Large Abnormalities on Magnetic Resonance Images
Arch Neurol 66:268-271, McKeon,A.,et al, 2009
Plasmablastic Lymphoma: CNS Involvement, Coexistence of Other Malignancies, Possible Viral Etiology, and Dismal Outcome
Ann Hematol 88:351-358, Ustun, C.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Acute Limbic Encephalitis and Glutamic Acid Decarboxylase Antibodies:A Reality?
J Neurosci 287:69-71, Blanc,F.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Intravenous Thrombolysis in Stroke Attributable to Cervical Artery Dissection
Stroke 40:37772-3776, Engelter,S.,et al, 2009
Intraventricular Fibrinolysis and Lumbar Drainage for Ventricular Hemorrhage
Stroke 40:3275-3280, Staykov,D.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
MRI Findings Associated With Acute Liver Failure
Neurol 72:2130-2131, Fridman,V.,et al, 2009
Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009
Transcranial Ultrasound in Clinical Sonothrombolysis (TUCSON) Trial
Ann Neurol 66:28-38, Molina,C.A.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009
Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants
Stroke 40:3547-3551, Rizos,T.,et al, 2009
Telemedicine Versus Telephone for Remote Emergency Stroke Consultations: A Critically Appraised Topic
The Neurologist 15:163-166, Capampngan,D.J.,et al, 2009
Neurologic Immune Reconstitution Inflammatory Syndrome in HIV/AIDS: Outcome and Epidemiology
Neurol 72:835-841, McCombe,J.A.,et al, 2009
PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009
Thrombolysis in Young Adults with Ischemic Stroke
Stroke 40:2085-2091, Putaala,J.,et al, 2009
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Stroke 40:2257-2261, Turan,T.N.,et al, 2009
4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009
MR Mismatch Is Useful for Patient Selection for Thrombolysis: Yes
Stroke 40:2906-2907,2910, Fiebach,J.B. &Schellinger,P.D., 2009
Parkinsonism in HIV-Infected Patients on Highly Active Antiretroviral Therapy
Neurol 73:401-403, Tisch,S. &Brew,B., 2009
Intraarterial Thrombolysis Within the First Three Hours After Acute Ischemic Stroke in Selected Patients
Stroke 40:2611-2612,2615, Moonis,M., 2009
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No
Stroke 40:2613-2614,2615, Lindley,R.I., 2009
Use of MRI to Estimate the Therapeutic Window in Acute Stroke: Is Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch an EPITHET for Salvageable Ischemic Brain Tissue?
Stroke 40:333-335, Toth,G. &Albers,G.W., 2009
Intravascular Lymphoma Masquerading as Multiembolic Stroke Developing After Coronary Artery By-Pass Surgery
The Neurologist 15:98-101, Sumer,M.,et al, 2009
Carbon Monoxide Poisoning
NEJM 360:1217-1225, Weaver,L.K., 2009
The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009
Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature
Stroke 40:801-807, Arnold,M.,et al, 2009